Policy / Pricing Pharma’s Reluctance To Serve Europe To Dodge MFN Drug Pricing Is Chilling BioSpaceAs Big Pharma companies consider foregoing European drug launches to avoid reducing drug prices in the U.S.Policy / PricingRead full story pharminent April 2, 2026 (Last updated: April 2, 2026) BioSpace As Big Pharma companies consider foregoing European drug launches to avoid reducing drug prices in the U.S. Policy / PricingRead full story Post navigation Previous: Pfizer, BioNTech Halt Large US COVID-19 Vaccine Trial Over Slow EnrollmentNext: ACC 2026: sotatercept meta-analysis backs disease-modifying role in PAH Related Stories Policy / Pricing UniQure, Replimune shares rise as FDA’s Makary exits, but path forward unchanged pharminent May 13, 2026 Policy / Pricing EU agrees plan to tackle essential medicine shortages pharminent May 12, 2026 Policy / Pricing 340B in 2026: Market Shifts, Policy Battles, and What They Mean for Stakeholders (NEW Live Video Webinar) pharminent May 12, 2026
